. * * window.aa needs to exist and be usable by ANY module's script, * however early it runs - main-nav's script, for one, runs near * the top of

91̽»¨

, well before the real search-insights.js * so the download * begins as early as before. Repeat calls share the same downloads, a * failed load is retried on the next call, and the versions / SRI * hashes live only here. * * Algolia Insights is unaffected: window.aa above is still created in * on every page and queues events until search-insights loads. * * window.loadAlgoliaLibs({ priority: 'high' }) (Oct 2026): used by the * /search page, where the first results wait on these libraries. Chrome * gives async scripts low priority, behind images and fonts; this asks * for high instead (fetchpriority). Only the first call for a library * sets its priority - later calls share that download. */ (function (win, doc) { var LIBS = [ { ready: function () { return !!win['algoliasearch/lite']; }, src: 'https://cdn.jsdelivr.net/npm/algoliasearch@5.52.1/dist/lite/builds/browser.umd.js', integrity: 'sha256-I2oYUIvhx1g6l4lTP+yoERbzLIHKzw4AKaBRQPwIeDY=' }, { ready: function () { return !!win.instantsearch; }, src: 'https://cdn.jsdelivr.net/npm/instantsearch.js@4.98.0/dist/instantsearch.production.min.js', integrity: 'sha256-ngmqZk4WBxUw257aMYZayyNBd983INngagv0jI6Ecfs=' } ]; function loadOne(lib, options) { if (lib.ready()) return Promise.resolve(); // One download per library, shared by every caller; reset on // failure so the next call retries just the library that failed. if (lib.pending) return lib.pending; lib.pending = new Promise(function (resolve, reject) { var script = doc.createElement('script'); script.src = lib.src; script.integrity = lib.integrity; script.crossOrigin = 'anonymous'; script.async = true; if (options && options.priority === 'high') script.setAttribute('fetchpriority', 'high'); script.onload = function () { lib.ready() ? resolve() : reject(new Error('Loaded but not available: ' + lib.src)); }; script.onerror = function () { script.remove(); reject(new Error('Could not load ' + lib.src)); }; doc.head.appendChild(script); }); lib.pending.catch(function () { lib.pending = null; }); return lib.pending; } win.loadAlgoliaLibs = function (options) { return Promise.all(LIBS.map(function (lib) { return loadOne(lib, options); })); }; })(window, document); . */ window.hsConversationsSettings = window.hsConversationsSettings || {}; window.hsConversationsSettings.loadImmediately = false; (function (win) { var EVENTS = ['pointerdown', 'keydown', 'touchstart', 'scroll', 'mousemove', 'wheel']; var done = false; /* 19 Oct 2026 - chat widget layout shift (field CLS). Phones fail Core Web Vitals on CLS (p75 ~0.2 site-wide in CrUX for months). Biggest cause found: HubSpot's chat container is fixed to the bottom-right corner and changes size - 100x96 launcher to 282x253 when the welcome message pops up (~5 s after load), and to full screen when a visitor opens the chat. Its top-left corner moves, so Chrome scores it as a layout shift: 0.088 per page view at 360x640 (0.044 at 412x850), on every page. Taps happen inside the chat iframe, so the parent page never sees the input and the open/close shifts count too. Fix: whenever the container's size changes it is made transparent for 400 ms (Chrome doesn't score shifts of invisible elements), then shown again at its new size. Tested on live io1001 at 360x640 in a cookie-less frame: the 0.088 shift no longer appears. The chat itself is unchanged - it just appears 0.4 s later at each resize. Relies on HubSpot's container id; if that changes this does nothing (no error). */ function cloakChatResizes() { var ID = 'hubspot-messages-iframe-container'; function watch(c) { if (c.getAttribute('data-bb-cloak')) return; c.setAttribute('data-bb-cloak', '1'); var last = c.offsetWidth + 'x' + c.offsetHeight, timer = null; new MutationObserver(function () { var size = c.offsetWidth + 'x' + c.offsetHeight; if (size === last) return; last = size; c.style.setProperty('opacity', '0', 'important'); clearTimeout(timer); timer = setTimeout(function () { c.style.removeProperty('opacity'); }, 400); }).observe(c, { attributes: true, attributeFilter: ['style', 'class'], subtree: true, childList: true }); } var found = document.getElementById(ID); if (found) { watch(found); return; } if (!document.body || !('MutationObserver' in win)) return; var mo = new MutationObserver(function () { var c = document.getElementById(ID); if (c) { mo.disconnect(); watch(c); } }); mo.observe(document.body, { childList: true }); setTimeout(function () { mo.disconnect(); }, 30000); } function loadWidget() { var api = win.HubSpotConversations; if (api && api.widget && api.widget.status && api.widget.status().loaded) return; try { cloakChatResizes(); } catch (e) {} if (api && api.widget) api.widget.load(); } function onFirstInteraction() { if (done) return; done = true; EVENTS.forEach(function (type) { win.removeEventListener(type, onFirstInteraction, { passive: true }); }); var start = function () { if (win.HubSpotConversations) loadWidget(); else (win.hsConversationsOnReady = win.hsConversationsOnReady || []).push(loadWidget); }; if ('requestIdleCallback' in win) win.requestIdleCallback(start, { timeout: 1500 }); else setTimeout(start, 200); } EVENTS.forEach(function (type) { win.addEventListener(type, onFirstInteraction, { passive: true }); }); })(window);

91̽»¨

Skip to main content
Sartorius application note - Advanced in vitro Modeling of Human iPSC-derived Neuronal Mono- and Co-cultures with Microglia
application note

Advanced in vitro Modeling of Human iPSC-derived Neuronal Mono- and Co-cultures with Microglia: Optimization Using Growth Factors and Live-Cell Analysis

In this application note, developed and published by Sartorius two case studies are presented using ioMicroglia, ioGlutamatergic Neurons HTT 50CAG and ioGlutamatergic Neurons. This work includes assays of Microglial cytokine responses. Additionally, an assessment of the neuronal dynamics in of glutamatergic neurons with Huntington’s disease mutations are compared to a wild type control, in mono- and co-culture.
Advanced in vitro Modeling of Human iPSC-derived Neuronal Mono- and Co-cultures with Microglia: Optimization Using Growth Factors and Live-Cell Analysis
In this application note, developed and published by Sartorius two case studies are presented using ioMicroglia, ioGlutamatergic Neurons HTT 50CAG and ioGlutamatergic Neurons. This work includes assays of Microglial cytokine responses. Additionally, an assessment of the neuronal dynamics in of glutamatergic neurons with Huntington’s disease mutations are compared to a wild type control, in mono- and co-culture.

Human induced pluripotent stem cell (iPSC) derived models are increasingly being used for in vitro studies of the human central nervous system. These models enable the generation of specific neurons and support cells and provide a more translational system for investigating human development and disease. Growth factors and cytokines are critical in these models for cell growth, differentiation, and survival, but their study is complicated by factors like unknown commercial media compositions and sensitivity to handling. To successfully use these advanced models, robust culture conditions and technology approaches to non-invasively optimise, visualise, and kinetically quantify these complex models are required.

In this application note, the Sartorius team examines the efficacy of Sartorius Research Use Only (RUO) Growth Factors and Cytokines for robustly maintaining iPSC-derived neuronal and microglial models in healthy and diseased states and demonstrate how the Incucyte® Live-Cell Analysis System facilitates their characterisation through non-invasive, continuous monitoring of culture health, morphology, marker expression, and function. 

In this application note, you will discover:

  • An integrated solution for the visualisation and quantification of long-term changes in the health, morphology, function, and marker expression in ioMicroglia and ioGlutamatergic Neuron cell models.
  • Methods for the robust co-culture of ioGlutamatergic Neuron models in healthy and diseased states with ioMicroglia utilizing Sartorius’ Research Use Only (RUO) Growth Factors and Cytokines.
  • A case study on the response of ioMicroglia following treatment with pro-inflammatory stimuli showing that these cells exhibit stellate morphology indicative of microglial activation. 
  • A case study on the quantification of dynamic changes of Huntington’s disease model ioGlutamatergic Neurons compared to a genetically matched control, monitoring their neurite length and branching. Calcium imaging assays revealed that co-culture of healthy and disease model ioGlutamatergic Neurons with ioMicroglia synchronised calcium bursts, and that these bursts were markedly different in the disease model.  

This application note was

Trigg et al.,
Sartorius
2024

Related pages

91̽»¨ Learn about our range of human iPSC-derived cells for research and drug discovery
Our platform Discover the cell coding platform behind our cells
Contact us Talk to us to learn more about our team and products